Literature DB >> 12049628

HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription.

Sergei Nekhai1, Meisheng Zhou, Anne Fernandez, William S Lane, Ned J C Lamb, John Brady, Ajit Kumar.   

Abstract

HIV-1 gene expression is regulated by a viral transactivator protein (Tat) which induces transcriptional elongation of HIV-1 long tandem repeat (LTR). This induction requires hyperphosphorylation of the C-terminal domain (CTD) repeats of RNA polymerase II (Pol II). To achieve CTD hyperphosphorylation, Tat stimulates CTD kinases associated with general transcription factors of the promoter complex, specifically TFIIH-associated CDK7 and positive transcription factor b-associated CDK9 (cyclin-dependent kinase 9). Other studies indicate that Tat may bind an additional CTD kinase that regulates the target-specific phosphorylation of RNA Pol II CTD. We previously reported that Tat-associated T-cell-derived kinase (TTK), purified from human primary T-cells, stimulates Tat-dependent transcription of HIV-1 LTR in vivo [Nekhai, Shukla, Fernandez, Kumar and Lamb (2000) Virology 266, 246-256]. In the work presented here, we characterized the components of TTK by biochemical fractionation and the function of TTK in transcription assays in vitro. TTK uniquely co-purified with CDK2 and not with either CDK9 or CDK7. Tat induced the TTK-associated CDK2 kinase to phosphorylate CTD, specifically at Ser-2 residues. The TTK fraction restored Tat-mediated transcription activation of HIV-1 LTR in a HeLa nuclear extract immunodepleted of CDK9, but not in the HeLa nuclear extract double-depleted of CDK9 and CDK7. Direct microinjection of the TTK fraction augmented Tat transactivation of HIV-1 LTR in human primary HS68 fibroblasts. The results argue that TTK-associated CDK2 may function to maintain target-specific phosphorylation of RNA Pol II that is essential for Tat transactivation of HIV-1 promoter. They are also consistent with the observed cell-cycle-specific induction of viral gene transactivation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12049628      PMCID: PMC1222613          DOI: 10.1042/BJ20011191

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  33 in total

Review 1.  Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation.

Authors:  R Taube; K Fujinaga; J Wimmer; M Barboric; B M Peterlin
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

2.  DNA binding provides a signal for phosphorylation of the RNA polymerase II heptapeptide repeats.

Authors:  S R Peterson; A Dvir; C W Anderson; W S Dynan
Journal:  Genes Dev       Date:  1992-03       Impact factor: 11.361

3.  Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator.

Authors:  F Kashanchi; E T Agbottah; C A Pise-Masison; R Mahieux; J Duvall; A Kumar; J N Brady
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 4.  Regulation of human immunodeficiency virus infection: implications for pathogenesis.

Authors:  B A Antoni; S B Stein; A B Rabson
Journal:  Adv Virus Res       Date:  1994       Impact factor: 9.937

5.  Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.

Authors:  C H Herrmann; A P Rice
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

6.  Purification of P-TEFb, a transcription factor required for the transition into productive elongation.

Authors:  N F Marshall; D H Price
Journal:  J Biol Chem       Date:  1995-05-26       Impact factor: 5.157

7.  PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro.

Authors:  X Graña; A De Luca; N Sang; Y Fu; P P Claudio; J Rosenblatt; D O Morgan; A Giordano
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts.

Authors:  M Adams; L Sharmeen; J Kimpton; J M Romeo; J V Garcia; B M Peterlin; M Groudine; M Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase.

Authors:  R P Fisher; P Jin; H M Chamberlin; D O Morgan
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

10.  Sequences within the R region of the long terminal repeat activate basal transcription from the HIV-1 promoter.

Authors:  K A Boris-Lawrie; J N Brady; A Kumar
Journal:  Gene Expr       Date:  1992
View more
  28 in total

1.  Transcriptional regulation of HIV-1 gene expression by p53.

Authors:  Ruma Mukerjee; Pier Paolo Claudio; J Robert Chang; Luis Del Valle; Bassel E Sawaya
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

2.  Use of ATP analogs to inhibit HIV-1 transcription.

Authors:  Aarthi Narayanan; Gavin Sampey; Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Jessica Roman; Robert Currer; Hervé Galons; Nassima Oumata; Benoît Joseph; Laurent Meijer; Massimo Caputi; Sergei Nekhai; Fatah Kashanchi
Journal:  Virology       Date:  2012-07-06       Impact factor: 3.616

3.  Interaction of Bunyamwera Orthobunyavirus NSs protein with mediator protein MED8: a mechanism for inhibiting the interferon response.

Authors:  Vincent H J Léonard; Alain Kohl; Timothy J Hart; Richard M Elliott
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 4.  Cyclin-dependent kinases as therapeutic targets for HIV-1 infection.

Authors:  Andrew P Rice
Journal:  Expert Opin Ther Targets       Date:  2016-11-10       Impact factor: 6.902

5.  Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner.

Authors:  Rajeev Mehla; Shalmali Bivalkar-Mehla; Ruonan Zhang; Indhira Handy; Helmut Albrecht; Shailendra Giri; Prakash Nagarkatti; Mitzi Nagarkatti; Ashok Chauhan
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

6.  The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients.

Authors:  Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Rebecca Easley; Zachary Klase; Chenglong Liu; Mary Young; Fatah Kashanchi
Journal:  AIDS Res Ther       Date:  2010-07-06       Impact factor: 2.250

7.  microRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection.

Authors:  Lawrence Carpio; Zachary Klase; William Coley; Irene Guendel; Sarah Choi; Rachel Van Duyne; Aarthi Narayanan; Kylene Kehn-Hall; Laurent Meijer; Fatah Kashanchi
Journal:  J RNAi Gene Silencing       Date:  2010-05-29

8.  Regulation of HIV-1 transcription at 3% versus 21% oxygen concentration.

Authors:  Sharroya Charles; Tatyana Ammosova; Jessica Cardenas; Altreisha Foster; Jamie Rotimi; Marina Jerebtsova; Abisola A Ayodeji; Xiaomei Niu; Patricio E Ray; Victor R Gordeuk; Fatah Kashanchi; Sergei Nekhai
Journal:  J Cell Physiol       Date:  2009-11       Impact factor: 6.384

9.  Role of cellular iron and oxygen in the regulation of HIV-1 infection.

Authors:  Sergei Nekhai; Namita Kumari; Subhash Dhawan
Journal:  Future Virol       Date:  2013-03       Impact factor: 1.831

10.  In vitro nuclear interactome of the HIV-1 Tat protein.

Authors:  Virginie W Gautier; Lili Gu; Niaobh O'Donoghue; Stephen Pennington; Noreen Sheehy; William W Hall
Journal:  Retrovirology       Date:  2009-05-19       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.